[Huanshao Capsules for erectile dysfunction with spleen and kidney deficiency: A multicentered clinical trial]

OBJECTIVE

To investigate the clinical efficacy and safety of Huanshao Capsules (HSC) in the treatment of ED with spleen and kidney deficiency.

METHODS

This randomized open multicentered positive drug controlled clinical trial included 248 cases of ED with spleen and kidney deficiency, which were assigned to a trial and a control group of equal number to be treated with HSC at the dose of 3 capsules tid and Wuziyanzong Pills at 6 g bid, respectively, both for 4 weeks. We recorded and compared the IIEF-5 scores, traditional Chinese medicine (TCM) symptom scores, and hepatic and renal functions between the two groups of patients before and at 2 and 4 weeks after medication.

RESULTS

The clinical observation was completed in 240 of the patients. Based on the IIEF-5 scores of the patients, the total effectiveness rate was significantly higher in the trial than in the control group (76.6% vs 67.8%, P < 0.05). The TCM symptom scores were decreased by ≥95% in 14 cases (11.7%), ≥70% in 97 cases (80.8%) and ≥30% in 9 cases (7.5%) in the trial group as compared with ≥95% in 7 cases (5.8%), ≥70% in 84 cases (70.0%) and ≥30% in 29 cases (24.2%) in the control, with remarkably better improvement in the former than in the latter group (P < 0.05). Before and at 2 and 4 weeks after medication, the IIEF-5 scores were 13.04 ± 4.02, 15.95 ± 3.22 and 20.06 ± 2.17, and the TCM symptom scores were 16.64 ± 5.26, 10.08 ± 4.89 and 3.05 ± 2.18 respectively in the trial group, both significantly improved at 4 weeks in comparison with those in the control (P < 0.05). No abnormality was observed in urine and blood tests or hepatic and renal functions before and after treatment, nor obvious adverse events were found in the two groups of patients during the medication.

CONCLUSIONS

Huanshao Capsules can safely and effectively improve the IIEF-5 scores and clinical symptoms of ED patients with spleen and kidney deficiency, and therefore deserve a wide clinical application.

[Huanshao Capsules for oligoasthenospermia: A multicentered clinical trial]

OBJECTIVE

To investigate the clinical efficacy and safety of Huanshao Capsules (HSC) in the treatment of oligoasthenospermia with spleen and kidney asthenia.

METHODS

This randomized, open, multicentered, positive drug controlled clinical trial included 200 cases of oligoasthenospermia with spleen and kidney asthenia, which were assigned to a trial and a control group of equal number to be treated with HSC at the dose of 3 capsules tid and Wuziyanzong Pills at 6 g bid, respectively, both for 12 weeks. We compared the semen volume, sperm concentration, sperm count, sperm motility and percentage of progressively motile sperm (PMS) as the main therapeutic indicators as well as the pregnancy rate as the secondary therapeutic indicator between the two groups of patients before and at 4, 8 and 12 weeks after medication.

RESULTS

Totally, 190 of the patients completed the clinical observation, 96 in the trial and 94 in the control group. Compared with the baseline, the patients of the trial group showed significant time-dependent increases at 4, 8 and 12 weeks after medication in the mean sperm concentration (14.78 vs 15.33, 20.98 and 28.78 ×10⁶/ml, P < 0.05), percentage of grade a sperm (12.17% vs 15.05%, 21.17% and 26.97%, P < 0.05), PMS (24.78% vs 28.97%, 37.23% and 47.67%, P < 0.05), and sperm viability (38.64% vs 44.18%, 51.67% and 60.45%, P < 0.05). The pregnancy rate was significantly higher in the trial than in the control group 29.17% vs 18.09%, P < 0.05).

CONCLUSIONS

Huanshao Capsules can improve the semen quality and pregnancy rate in the treatment of oligoasthenospermia patients with spleen and kidney asthenia, and therefore deserves a wide clinical application.